Form 4: Blueprint Medicines Director Albers Executes Stock Option and Sells Shares
SEC Form 4 Filing
Director Jeffrey W. Albers exercised stock options and sold shares of Blueprint Medicines Corp. on November 7, 2024, according to a Form 4 filing.
Summary
- On November 7, 2024, Jeffrey W. Albers, a director of Blueprint Medicines Corp., exercised stock options to acquire 5,000 shares of common stock at a price of $36.05 per share.
- Simultaneously, Albers sold 5,000 shares of common stock at $102 per share.
- These transactions were executed under a pre-arranged trading plan adopted on May 8, 2024, in accordance with Rule 10b5-1.
- Following these transactions, Albers directly owns 157,557 shares of Blueprint Medicines Corp. common stock and holds options for 135,000 shares.
Sentiment
Score: 5
Explanation: Neutral. This is a standard Form 4 filing indicating insider trading activity. The transactions were pre-planned, so there's no immediate cause for alarm or excitement.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives and directors to have pre-arranged trading plans to avoid accusations of trading on inside information. The sale could be for personal financial planning reasons.
Key Dates
| Date | Description |
|---|---|
| 02/16/2017 | Date the stock option was granted. |
| 05/08/2024 | Date the trading plan was adopted. |
| 11/07/2024 | Date of the stock option exercise and share sale. |
| 11/08/2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.